Methods of treatment using CTLA4 mutant molecules

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10370428
APP PUB NO 20170369549A1
SERIAL NO

15668824

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • BRISTOL MYERS SQUIBB COMPANY

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bajorath, Jurgen Bonn, DE 34 1052
Linsley, Peter S Seattle, US 87 3622
Naemura, Joseph Bellevue, US 6 18
Peach, Robert James San Diego, US 32 363

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 6, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 6, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00